GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » CardioGenics Holdings Inc (OTCPK:CGNH) » Definitions » Return-on-Tangible-Equity

CardioGenics Holdings (CardioGenics Holdings) Return-on-Tangible-Equity : 0.00% (As of Jan. 2016)


View and export this data going back to 2004. Start your Free Trial

What is CardioGenics Holdings Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. CardioGenics Holdings's annualized net income for the quarter that ended in Jan. 2016 was $-0.50 Mil. CardioGenics Holdings's average shareholder tangible equity for the quarter that ended in Jan. 2016 was $-1.78 Mil. Therefore, CardioGenics Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Jan. 2016 was N/A%.

The historical rank and industry rank for CardioGenics Holdings's Return-on-Tangible-Equity or its related term are showing as below:

CGNH's Return-on-Tangible-Equity is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -1.945
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

CardioGenics Holdings Return-on-Tangible-Equity Historical Data

The historical data trend for CardioGenics Holdings's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CardioGenics Holdings Return-on-Tangible-Equity Chart

CardioGenics Holdings Annual Data
Trend Jul06 Jul07 Jul08 Oct09 Oct10 Oct11 Oct12 Oct13 Oct14 Oct15
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -413.96 -568.70 - - -

CardioGenics Holdings Quarterly Data
Apr11 Jul11 Oct11 Jan12 Apr12 Jul12 Oct12 Jan13 Apr13 Jul13 Oct13 Jan14 Apr14 Jul14 Oct14 Jan15 Apr15 Jul15 Oct15 Jan16
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - Negative Tangible Equity - - -

Competitive Comparison of CardioGenics Holdings's Return-on-Tangible-Equity

For the Diagnostics & Research subindustry, CardioGenics Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CardioGenics Holdings's Return-on-Tangible-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, CardioGenics Holdings's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where CardioGenics Holdings's Return-on-Tangible-Equity falls into.



CardioGenics Holdings Return-on-Tangible-Equity Calculation

CardioGenics Holdings's annualized Return-on-Tangible-Equity for the fiscal year that ended in Oct. 2015 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Oct. 2015 )  (A: Oct. 2014 )(A: Oct. 2015 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Oct. 2015 )  (A: Oct. 2014 )(A: Oct. 2015 )
=-1.916/( (-1.263+-1.666 )/ 2 )
=-1.916/-1.4645
=N/A %

CardioGenics Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Jan. 2016 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jan. 2016 )  (Q: Oct. 2015 )(Q: Jan. 2016 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jan. 2016 )  (Q: Oct. 2015 )(Q: Jan. 2016 )
=-0.5/( (-1.666+-1.888)/ 2 )
=-0.5/-1.777
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jan. 2016) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


CardioGenics Holdings  (OTCPK:CGNH) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


CardioGenics Holdings Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of CardioGenics Holdings's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


CardioGenics Holdings (CardioGenics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
6295 Northam Drive, Unit 8, Mississauga, ON, CAN, L4V 1W8
CardioGenics Holdings Inc is a biotechnology company. It is engaged in the development and commercialization of diagnostic test products for the In-Vitro Diagnostics (IVD) testing market. The company's objective is to create, develop and commercialize superior, innovative, cost-effective and patent-protected products for the IVD based on proprietary technologies. Its products include QL Care Analyzer, Immunoassay Tests, and Paramagnetic Beads. The business activity is primarily carried out through the region of Canada.

CardioGenics Holdings (CardioGenics Holdings) Headlines

No Headlines